JP4412521B2 - sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体 - Google Patents

sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体 Download PDF

Info

Publication number
JP4412521B2
JP4412521B2 JP2000542326A JP2000542326A JP4412521B2 JP 4412521 B2 JP4412521 B2 JP 4412521B2 JP 2000542326 A JP2000542326 A JP 2000542326A JP 2000542326 A JP2000542326 A JP 2000542326A JP 4412521 B2 JP4412521 B2 JP 4412521B2
Authority
JP
Japan
Prior art keywords
ethyl
pyrazin
methyl
oxamoylpyrrolo
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000542326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002530268A5 (cg-RX-API-DMAC7.html
JP2002530268A (ja
Inventor
光昭 大谷
雅弘 冨士
哲夫 岡田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JP2002530268A publication Critical patent/JP2002530268A/ja
Publication of JP2002530268A5 publication Critical patent/JP2002530268A5/ja
Application granted granted Critical
Publication of JP4412521B2 publication Critical patent/JP4412521B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2000542326A 1998-03-31 1999-03-31 sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体 Expired - Fee Related JP4412521B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP10-85997 1998-08-31
JP24473598 1998-08-31
JP10-244735 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (3)

Publication Number Publication Date
JP2002530268A JP2002530268A (ja) 2002-09-17
JP2002530268A5 JP2002530268A5 (cg-RX-API-DMAC7.html) 2009-11-12
JP4412521B2 true JP4412521B2 (ja) 2010-02-10

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542326A Expired - Fee Related JP4412521B2 (ja) 1998-03-31 1999-03-31 sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体

Country Status (11)

Country Link
US (1) US6407104B1 (cg-RX-API-DMAC7.html)
EP (1) EP1066290A1 (cg-RX-API-DMAC7.html)
JP (1) JP4412521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010042307A (cg-RX-API-DMAC7.html)
CN (1) CN1303384A (cg-RX-API-DMAC7.html)
AU (1) AU3054399A (cg-RX-API-DMAC7.html)
BR (1) BR9909345A (cg-RX-API-DMAC7.html)
CA (1) CA2326522A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0102981A3 (cg-RX-API-DMAC7.html)
NO (1) NO20004881L (cg-RX-API-DMAC7.html)
WO (1) WO1999051605A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042716A1 (ja) * 2021-09-17 2023-03-23 三井化学株式会社 (メタ)アクリルアミド化合物の製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 sPLA2阻害作用を有する三環系化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (en) * 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an spla2- inhibiting effect
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
JP2004505982A (ja) * 2000-08-04 2004-02-26 イーライ・リリー・アンド・カンパニー 新規なsPLA2インヒビター
TWI314457B (cg-RX-API-DMAC7.html) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP1950200B1 (en) 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
IL124871A (en) 1995-12-13 2002-04-21 Lilly Co Eli Naphthyl glyoxamides and medicinal preparations containing them, as inhibitors of sPLA2
DE69614232T2 (de) 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042716A1 (ja) * 2021-09-17 2023-03-23 三井化学株式会社 (メタ)アクリルアミド化合物の製造方法
JPWO2023042716A1 (cg-RX-API-DMAC7.html) * 2021-09-17 2023-03-23
JP7696436B2 (ja) 2021-09-17 2025-06-20 三井化学株式会社 (メタ)アクリルアミド化合物の製造方法

Also Published As

Publication number Publication date
US6407104B1 (en) 2002-06-18
HUP0102981A3 (en) 2002-10-28
CN1303384A (zh) 2001-07-11
BR9909345A (pt) 2000-12-12
EP1066290A1 (en) 2001-01-10
JP2002530268A (ja) 2002-09-17
AU3054399A (en) 1999-10-25
KR20010042307A (ko) 2001-05-25
CA2326522A1 (en) 1999-10-14
HUP0102981A2 (hu) 2002-01-28
NO20004881D0 (no) 2000-09-28
WO1999051605A1 (en) 1999-10-14
NO20004881L (no) 2000-11-28

Similar Documents

Publication Publication Date Title
JP4544446B2 (ja) sPLA2阻害作用を有するピロロ[1,2−b]ピリダジン誘導体
JP4623483B2 (ja) sPLA2阻害作用を有するピロロトリアジン誘導体
JPWO1999059999A1 (ja) sPLA2阻害作用を有するピロロ[1,2−b]ピリダジン誘導体
JPWO2001014378A1 (ja) sPLA2阻害作用を有するピロロトリアジン誘導体
JP2002530268A (ja) sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体
JP5680146B2 (ja) Crth2受容体拮抗薬としての複素環化合物
JP4972644B2 (ja) Crth2受容体拮抗薬としてのインドール誘導体
AU753547B2 (en) Substituted tricyclics
EA020816B1 (ru) Ингибиторы вирусов flaviviridae
CN101484449A (zh) 整合酶抑制剂-3
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
CN111566102A (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
US20030181454A1 (en) Compounds exhibiting x-type spla2 inibiting effect
US6756376B1 (en) Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
TW202506666A (zh) Il-17a的小分子調節劑、其製備方法和使用方法
JPH09510700A (ja) エンケファリナーゼ阻害剤として有用な新規なインダン−2−メルカプトアセチルアミドジスルフィド誘導体類
JP4636521B2 (ja) sPLA2阻害作用を有する三環系化合物
JP4636522B2 (ja) sPLA2阻害作用を有する三環式化合物
JPWO2001005789A1 (ja) sPLA2阻害作用を有する三環系化合物
JPWO2001009130A1 (ja) sPLA2阻害作用を有する三環式化合物
JP5841361B2 (ja) 三環性化合物及びそれを含有する医薬組成物
JPWO2001036420A1 (ja) sPLA2阻害作用を有する三環性アザインドリジン誘導体
MXPA00011018A (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2
CZ20003193A3 (cs) Sloučenina pyrrolo[l,2-a]pyrazinu, proléčivo, farmaceutický prostředek a metoda inhibující sPLA2
MXPA00009418A (en) PYRROLO[1,2-a]PYRAZINE sPLA2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121127

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees